营收暴增555%，毛利率近80%，这家“减肥企业”要上市！

Core Viewpoint - Hangzhou Tangji Medical Technology Co., Ltd. is seeking to list on the Hong Kong Stock Exchange, focusing on minimally invasive endoscopic interventions in the weight loss market, aiming to carve out a "third path" between drug therapies and traditional surgical methods [1][2]. Company Overview - Founded in 2016, Tangji Medical specializes in innovative medical device solutions for metabolic diseases, including obesity and related conditions [2]. - The company has developed the world's first approved endoscopic device for treating obesity, known as the Gastric Bypass Stent (GBS), which is a Class III innovative medical device [2]. Market Potential - The global weight loss market is polarized, with GLP-1 receptor agonists like semaglutide generating projected sales of $36.1 billion by 2025, while traditional metabolic surgeries remain effective but invasive [2]. - The market for endoscopic weight loss and metabolic treatment devices is expected to grow from $162.3 million in 2024 to $831.8 million by 2029, with a compound annual growth rate (CAGR) of 38.7% [2]. Product Description - The GBS is a flexible, retrievable sleeve that creates a physical barrier between the intestinal mucosa and food, allowing for a one-time intervention without the need for long-term medication [3]. - It is designed to be minimally invasive, reversible, and does not damage the body's structure, achieving fat loss without muscle loss [3]. Financial Performance - For the first nine months of 2025, the company reported revenue of 20.86 million yuan, a significant increase of 554.8% from 3.186 million yuan in the same period the previous year [4]. - The gross margin improved from 70.2% to 78.7% during the same period, attributed to the low material costs of the GBS once R&D expenses are amortized [4]. Financial Challenges - Despite revenue growth, the company faced substantial losses, with net losses of 65.96 million yuan for 2024 and 54.94 million yuan for the first nine months of 2025 [5]. - Operating expenses reached 69.76 million yuan in the first nine months of 2025, with R&D costs accounting for 46.6% of total expenses, exceeding revenue [5]. - As of September 30, 2025, the company had a negative cash flow of 49.04 million yuan and total liabilities of 106 million yuan, indicating a net debt situation [5].